Oleanolic acid exerts bone protective effects in ovariectomized mice by inhibiting osteoclastogenesis

Area of Science:

• Biochemistry
• Pharmacology
• Cell Biology

Background:

• Postmenopausal osteoporosis (POP) is a prevalent condition with ongoing drug development.
• Oleanolic acid (OA) has shown potential in preventing bone loss, but its role in osteoclastogenesis is unclear.
• Understanding OA's mechanism is crucial for developing effective POP treatments.

Purpose of the Study:

• To investigate the effect of Oleanolic acid (OA) on receptor activator of nuclear factor kappa-B ligand (RANKL)-mediated osteoclastogenesis.
• To elucidate the molecular mechanisms underlying OA's action on osteoclast formation.
• To evaluate OA's therapeutic potential for postmenopausal osteoporosis.

Main Methods:

• Dose-dependent inhibition of RANKL-mediated osteoclastogenesis in vitro.
• Assessment of OA's effect on osteoclast formation and viability in bone marrow macrophages (BMMs).
• In vivo studies in ovariectomized (OVX) mice to evaluate OA's effect on bone loss and osteoclast density.
• Analysis of signaling pathways (NF-κB, JNK, p38, Akt) and gene expression (NFATc1, c-Fos, MMP9, Cathepsin K, TRAP, Car2).

Main Results:

• OA dose-dependently inhibited RANKL-induced osteoclastogenesis and functional osteoclast formation without affecting BMM viability.
• OA administration attenuated bone loss in OVX mice by reducing osteoclast densities.
• OA suppressed the expression of key osteoclastogenic genes (NFATc1, c-Fos, MMP9, Cathepsin K, TRAP, Car2) but did not affect major signaling pathways.

Conclusions:

• Oleanolic acid effectively inhibits RANKL-mediated osteoclastogenesis by downregulating specific gene expression.
• OA demonstrates therapeutic potential for preventing and treating postmenopausal osteoporosis by reducing bone resorption.
• Further development of OA as a novel therapeutic agent for POP is warranted.